ENTITY
Abbvie Inc

Abbvie Inc (ABBV US)

174
Analysis
Health CareUnited States
AbbVie Inc. researches and develops pharmaceutical products. The Company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, Hepatitis C, women's health, oncology, and neuroscience. AbbVie also offers treatments for diseases including Multiple Sclerosis, Parkinson's, and Alzheimer's disease.
more
Refresh
bullishS&P 500 INDEX
30 Oct 2019 04:35

U.S. Equity Strategy: Dramatic Improvement

Encouraging developments continue to pour in. Over the past week we have seen dramatic improvements that could be setting the stage for a...

Logo
389 Views
Share
bullishAllergan Plc
31 Aug 2019 08:47

Allergan Plc Acquisition by AbbVie Inc. – A Botox Deal with Some Wrinkles

On June 25, 2019, Abbvie Inc (ABBV US) announced its acquisition of Botox-maker Allergan Plc (AGN US) in a $63 billion cash and stock deal in which...

Logo
615 Views
Share
21 Aug 2019 02:46

Shanghai Henlius Biotech IPO Initiation: Going Large

Shanghai Henlius Biotech (1566213D HK) is a biopharmaceutical company and a non-wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group)...

Logo
643 Views
Share
06 Feb 2019 11:41

Biosimilar Battlefield: The Remsima/Inflectra Warning

2019 marks an inflection point for Korean biosimilar companies Celltrion Healthcare (091990 KS), Celltrion Inc (068270 KS), and Samsung Biologics...

Share
18 Jan 2019 11:41Syndicated

Celgene and Bristol-Myers Squibb – Undervalued and Underappreciated

A dismal 2018 for the pharmaceutical and bio-tech stocks seems far in the rear view mirror. 2019 began with a bang with two blockbuster deals in...

Logo
669 Views
Share
x